Brought to you by 
Cephalon snubs Valeant, agrees to $6.8bn acquisition by Teva
May 2011
Executive Summary
Just over a month after receiving a hostile offer from Valeant Pharmaceuticals International Inc., leading biotechnology company Cephalon Inc. has signed a definitive agreement to be acquired instead by Teva Pharmaceutical Industries Ltd. for $81.50 in cash per share, a 45% premium to the ten-day average prior to Valeant’s announcement in late March. The new deal values Cephalon at $6.8bn based on the 76.2mm shares outstanding on April 8, 2011 (the most recent figure available), plus $594mm in assumed debt.
Deal Industry
- Biotechnology
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Cash
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Cephalon snubs Valeant, agrees to $6.8bn acquisition by Teva
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice